Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Five Prime Therapeutics, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day 
Tickers FPRX
From Business Wire News Releases
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ G
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemo 
Tickers FPRX
From Business Wire News Releases
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology Gastrointestinal Cancers Annual Symposium 
Tickers FPRX
From Business Wire News Releases
Five Prime Announces Closing of Upsized Public Offering of Common Stock
Five Prime Announces Closing of Upsized Public Offering of Common Stock 
Tickers FPRX
From Business Wire News Releases
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share. The... 
Tickers FPRX
From Business Wire News Releases
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157 
Tickers FPRX
From Business Wire News Releases
Five Prime Announces Proposed Public Offering of Common Stock
Five Prime Announces Proposed Public Offering of Common Stock 
Tickers FPRX
From Business Wire News Releases
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gas
Five Prime Announces Bemarituzumab Plus Chemo Demonstrates Significant PFS and OS Benefit Compared to Placebo Plus Chemo in Front-line Gastric Cancer 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Reports Third Quarter 2020 Results
Five Prime Therapeutics Reports Third Quarter 2020 Results 
Tickers FPRX
From Business Wire News Releases
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Reports Second Quarter 2020 Results
Five Prime Therapeutics Reports Second Quarter 2020 Results 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Reports First Quarter 2020 Results
Five Prime Therapeutics Reports First Quarter 2020 Results 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call
Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Present at Upcoming Healthcare Conference
Five Prime Therapeutics to Present at Upcoming Healthcare Conference 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer
Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call
Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call 
Tickers FPRX
From Business Wire News Releases
Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference 
Tickers FPRX
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.